IDE Approval Received from the FDA for the SWIFT multi-centre, open, randomized, controlled, parallel-group, blind-assessed trial

IDE approval was received in April 2022 from the FDA for the SWIFT multi-centre, open, randomized, controlled, parallel-group, blind-assessed trial.

The primary objective of this trial is to collect fully independent clinical evidence of the effectiveness of the Swift device for the treatment of common and plantar warts as compared with Cryotherapy.

The secondary objectives of this study are to collect evidence of the safety, effectiveness, and patient experiences of the Swift device for the treatment of common and plantar warts.

The trial (NCT05371834) will be conducted in the US across three sites with an estimated enrolment of 110 participants.